Journal
JACC-CARDIOVASCULAR INTERVENTIONS
Volume 15, Issue 23, Pages 2427-2436Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2022.09.011
Keywords
catheter; directed therapy; pulmonary embolism; thrombolysis; refined modified Miller index; RV/LV ratio
Categories
Funding
- National Heart, Lung, and Blood Institute (NHLBI) [R44HL151032-03]
- Commonwealth of Pennsylvania Department of Health
- Thrombolex
- EKOS
- BTG International Group company
- Bayer
- Bristol Myers Squibb/Pfizer Alliance
- Daiichi-Sankyo
- Portola
- Janssen
- National Institutes of Health
Ask authors/readers for more resources
This study evaluated the efficacy and safety of a pharmacomechanical catheter-directed thrombolysis (CDT) device called the Bashir endovascular catheter in patients with intermediate-risk acute pulmonary embolism (PE). The results showed a significant reduction in the RV/LV diameter ratio, PA obstruction, and low rates of adverse events or major bleeding.
BACKGROUND Catheter-directed thrombolysis (CDT) has been associated with rapid recovery of right ventricular (RV) function. The Bashir catheter was developed for enhanced thrombolysis in large vessels such as the pulmonary arteries (PAs) with lower doses of tissue plasminogen activator (tPA). OBJECTIVES The aim of this study was to evaluate the efficacy and safety of tPA infused using a pharmacomechanical (PM) CDT device called the Bashir endovascular catheter in patients with intermediate-risk acute pulmonary embolism (PE). METHODS Patients with symptoms of acute PE with computed tomographic evidence of RV dilatation were enrolled. The Bashir catheter was used to deliver 7 mg tPA into each PA over 5 hours. The primary efficacy endpoint was the core laboratory-assessed change in computed tomographic angiography-derived RV/left ventricular (LV) diameter ratio at 48 hours, and the primary safety endpoint was serious adverse events (SAEs) including major bleeding at 72 hours. RESULTS At 18 U.S. sites, 109 patients were enrolled. The median device placement time was 15 minutes. At 48 hours after PM-CDT, the RV/LV diameter ratio decreased by 0.56 (33.3%; P < 0.0001). PA obstruction as measured by the refined modified Miller index was reduced by 35.9% (P < 0.0001). One patient (0.92%) had 2 SAEs: a retroperitoneal bleed (procedure related) and iliac vein thrombosis (device related). Two other procedure-related SAEs were epistaxis and non-access site hematoma with anemia. CONCLUSIONS PM-CDT with the Bashir endovascular catheter is associated with a significant reduction in RV/LV diameter ratio and a very low rate of adverse events or major bleeding in patients with intermediate-risk acute PE. The notable finding was a significant reduction in PA obstruction with low-dose tPA. (Recombinant tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden [RESCUE]; NCT04248868) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available